Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 2129-2134, 2006. First published September 21, 2006; 10.1373/clinchem.2006.073148
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.073148v1
52/11/2129    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kazmierczak, S. C.
Right arrow Articles by Muravsky, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kazmierczak, S. C.
Right arrow Articles by Muravsky, V.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2006;52:2129-2134.)
© 2006 American Association for Clinical Chemistry, Inc.

Oak Ridge Conference

Electron Spin Resonance Spectroscopy of Serum Albumin: A Novel New Test for Cancer Diagnosis and Monitoring

Steven C. Kazmierczak1,a, Andrey Gurachevsky2, Gert Matthes3 and Vladimir Muravsky2

1 Department of Pathology, Oregon Health & Science University, Portland, OR.
2 MedInnovation GmbH, Wildau, Germany.
3 Institute of Transfusion Medicine, University Hospital Leipzig, Germany.

aAddress correspondence to this author at: Department of Pathology, Oregon Health & Science University, Mailcode: L-471, Portland, OR 97239. Fax 503-494-8148, e-mail kazmierc{at}ohsu.edu.


Abstract

Background: Proteins released by tumor cells can bind to serum albumin, leading to structural and functional modifications. We used electron spin resonance (ESR) spectroscopy to measure these changes in serum albumin and evaluate their utility for the diagnosis and monitoring of cancer.

Methods: We used an ESR spectrometer and 16-doxyl stearic acid as spin probe to measure conformational changes in albumin in blood samples from a population of healthy donors and volunteers (n = 349), patients with a wide variety of hematologic and nonhematologic malignancy (n = 135), and patients with chronic diseases such as gastrointestinal and pulmonary disease, diabetes, and cirrhosis (n = 91). We added differing amounts of 16-doxyl stearic acid spin probe in ethanol to 50 µL of serum from each patient to create 3 different aliquots that differed in concentration of spin probe and ethanol, then incubated the aliquots for 10 min at 37 °C with continuous shaking. We measured the ESR spectra of each aliquot in triplicate and used proprietary software (MedInnovation GmbH) to evaluate the ESR spectrum for differences between cancer patients and the other groups.

Results: The diagnostic sensitivity and specificity of this test were 87.4% and 95.7%, respectively, for differentiating healthy individuals from cancer patients and 87.4%, and 85.7% for differentiating cancer patients from chronic disease patients. Serial evaluation of albumin conformation changes in several patients followed during the course of their disease showed excellent agreement between the magnitude of abnormality in the ESR spectrum of albumin and clinical and pathologic estimates of disease severity.

Conclusions: ESR spectroscopy of serum albumin is a sensitive and noninvasive technique that clearly demonstrates diagnostic utility in patients with cancer. This test also enables monitoring of the disease course through use of serial measurements.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.